Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
|
|
- Buddy Nash
- 5 years ago
- Views:
Transcription
1 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology & Biomedical Association April 15, 2014
2 Trend in R&D Efficiency Number of Drugs per Billion US$ R&D Spending Source: Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington, Diagnosing the decline in pharmaceutical R&D efficiency, Nature Reviews Drug Discovery 11, (March 2012) 2014 Eli Lilly and Company 2
3 $ billion NIH Program Level in Nominal Dollars and Constant 1998 Dollars Appropriation Appropriation in 1998 Dollars *Post-sequester **President s Budget Source: National Institutes of Health 2014 Eli Lilly and Company 3
4 Pharmaceutical Industry Consolidation Mergers have reduced the industry to a few major players DATES DEALS WERE ANNOUNCED Lilly 135 Pfizer Glaxo-Smith Kline Sanofi-Aventis Squibb Bristol-Myers Novartis Astra-Zeneca Genentech (Roc he ha s held a ma jority sta ke sinc e 1990 a nd fully a c q uired in 2009.) Bristol-Myers Squibb Bristol-Myers Squibb Lilly Merck Roche Independent centers of innovation are declining Mergers have been a significant disruptive force on the industry Lilly is unique among the major pharma The New York Times. Sources: Credit Suisse; company reports; Bloomberg 2014 Eli Lilly and Company 4
5 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
6 Science Has Made Dramatic Advances Decline in the cost of sequencing a human genome Logarithmic Scale $100,000,000 Cost per Genome $10,000,000 $1,000,000 $100,000 $10,000 The cost per genome has declined from $95,000,000 in Sept to $5,000 in Oct $1,000 Jan-01 Jan-02 Jan-03 Jan-04 Jan-05 Jan-06 Jan-07 Jan-08 Jan-09 Jan-10 Jan-11 Jan-12 Jan-13 Jan-14 Source: NIH, National Human Genome Research Institute 2014 Eli Lilly and Company 6
7 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
8 External Innovation Ecosystem Internal Innovation Ecosystem Building Sustainable R&D at Lilly Boosting internal efforts with access to external innovation Assets Technologies Capabilities Public-Private Partnerships Licensing Ventures Open Innovation Risk Share Academia Merger & Acquisition Integration Discovery Phase I Phase II Phase III Lilly Pipeline Eli Lilly and Company 8
9 Open Innovation Drug Discovery Year-end Affiliations in 34 Countries University Small Biotech 2014 Eli Lilly and Company 9
10 Project-Focused Companies (PFCs) Lilly Contributions: Capital Compounds Capabilities Lilly & Other Investors VC General Partner Candidates licensed from Lilly or 3 rd Party > $250 M in funds for up to 25 PFCs POCs sold to Lilly or 3 rd Party LLY PFC LLY PFC LLY PFC 3 rd Party PFC 3 rd Party PFC 3 rd Party PFC Chorus Other Engines 2014 Eli Lilly and Company 10
11 New Vehicles to Access and Advance Clinical-Stage Molecules Model/Company Therapeutic Area Investors Origin of Asset PFC: Arteaus Migraine Atlas Venture OrbiMed Advisors Lilly PFC: Tensha Oncology HealthCare Ventures Academia PFC: Dekkun Oncology HealthCare Ventures Lilly PFC: Anexon CV HealthCare Ventures Academia PFC: Kaneq Diabetes TVM Pharma PFC: Ixchelsis Men s Health TVM Pharma PFC: GITR Oncology HealthCare Ventures Biotech PFC: Apofore Diabetes HealthCare Ventures Academia PFC: GLWL Research Diabetes TVM Lilly Option: Transition Therapeutics OA Pain Lilly Option: Transition Therapeutics Diabetes Lilly PFC = Project-Focused Company 2014 Eli Lilly and Company 11
12 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
13 Lilly R&D Network Discovery Phase I Phase II Phase III Lilly Pipeline Internal Research Functional Outsourcing Corporate Venture Capital Early Stage Funds Public Private Partnerships Consortia Collaborations Academic Hubs In-licensing Open Innovation (OIDD) Internal Research & Development Functional Outsourcing Capital Funds (Project Focused Companies) Corporate Venture Capital Public Private Partnerships Consortia Co-Development In-licensing Chorus Internal Development Functional Outsourcing Public Private Partnerships Consortia Strategic Alliances Co-Development In-licensing 2014 Eli Lilly and Company 13
14 Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
State of Licensing 2011 Update
State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-
More informationMixed Signals: Understanding the Outlook for Pharma R&D Spending Through
Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,
More informationHow attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners
How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost
More informationPerspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond
Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,
More informationEmcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationLife Sciences Outlook
New Jersey 2018 JLL Research Report Life Sciences Outlook Breakthrough discoveries at a breathtaking pace 2 New Jersey The pharmaceutical/life sciences industry has historically been one of New Jersey
More informationNektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
More informationGLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS
GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS PHM006K March 2016 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-254-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationCASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
More informationJOHN JACK R. TUPMAN, JR CURRICULUM VITAE
JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant
More informationWOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
More informationPHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back.
Renew-New PHARMA S NEW PHASE Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom They re back. Mergers & acquisitions, that is and in a big way. Wall Street and City
More informationLife Sciences Outlook. New York City 2016
Life Sciences Outlook City 2016 City is emerging as a leading destination for biotech startups and the larger life sciences industry. Investors have committed millions of dollars throughout the city and
More informationTRANSLATIONAL SCIENCE
TRANSLATIONAL SCIENCE A Discussion of Best Practices and Unique Models Wednesday January 31, 2018 at The NYSCF Research Institute HRA TRI-STATE REGIONAL MEETING 31 Wednesday January, 2018 AGENDA 8:30 AM
More informationPwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update
PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease
More informationAugust 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio
Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members
More informationAssociate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive
Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager
More informationTransforming the right molecules into the best medicines TM
August 2017 Transforming the right molecules into the best medicines TM We are passionate in our mission to improve the health of patients by providing novel strategic alternatives to companies wishing
More informationScripps Florida. Accelerating Discoveries, Saving Lives. Presentation to the Urban Land Institute November 4, 2011
Scripps Florida Accelerating Discoveries, Saving Lives Presentation to the Urban Land Institute November 4, 2011 Alex Bruner Associate Vice President, Philanthropy 1921- Founding of the Scripps Metabolic
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID
More informationGrowing the pipeline, growing the bottom line. Shifts in pharmaceutical R&D innovation. kpmg.com KPMG INTERNATIONAL
Growing the pipeline, growing the bottom line Shifts in pharmaceutical R&D innovation kpmg.com KPMG INTERNATIONAL CONTENTS Page 4 The great research challenge Page 8 Organizational barriers to innovation
More informationLife Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research
Life Sciences New Jersey 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research 2 New Jersey Over the course of the past 130 years, the pharmaceutical/life sciences
More informationInnovating 4 DSM
Innovating 4 Change @ DSM Lessons from 1995 ~ 2015 Rob Kirschbaum, CEO SakuragiConsult (former VP Open Innovation DSM) Micro MBA, Breukelen, October, 2017 Introduction to Royal DSM Strategy; Emerging Business
More informationOmeros Raises More Than $63 Million in Financing
Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,
More informationThe MoneyTree Report. Overview of Venture Capital Investments Third Quarter 2009
The MoneyTree Report Overview of Venture Capital Investments Third Quarter 2009 PricewaterhouseCoopers/National Venture Capital Association MoneyTree Report based on data from Thomson Reuters 1 Host of
More informationVanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited
More informationPwC Deals $119.1B. Executive summary. Global Pharma & Life Sciences Deals Insights Q2 2018
PwC Deals Global Pharma & Life Sciences Deals Insights Q 18 The increase in deal activity in Q 18 sets the stage for a strong second half of the year. Companies continue to review their portfolios for
More informationNVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations
February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and
More informationPANEL DISCUSSION & ROUNDTABLES
LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the
More informationBiotech Concerto #6 Investment Process December 2008
Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision
More informationA Vision for Health Research and Innovation in Canada
A Vision for Health Research and Innovation in Canada Natalie Dakers President and CEO. Transforming Opportunity into Value 1 The Return on Public Investments in Research Have Not Been Maximized Net Royalty
More informationStrong Equity Support
Strong Equity Support Avista team has an intimate i knowledge of the offshore drilling business Avista s Co-Managing Partner, Steve Webster, founded Falcon Drilling and served at its CEO and R&B Falcon
More informationInnovation and the Changing Practice of Medicine
Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis
More informationAcadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationData-Driven Evaluation: The Key to Developing Successful Pharma Partnerships
R&D Solutions for PHARMA & LIFE SCIENCES DRUG DISCOVERY & DEVELOPMENT Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships Summary For pharmaceutical companies to succeed, it is
More informationThe 2011 EU industrial R&D investment SCOREBOARD
1 The 2011 EU industrial R&D investment SCOREBOARD Joint Research Centre European Commission Héctor Hernández Alex Tuebke Fernando Hervás 1. Background 2 Understanding the dynamics of industrial R&D at
More informationUtrecht Region. At the heart of the Netherlands Life Sciences and Health industry. Why locate your life sciences company in the Utrecht Region?
Utrecht Region At the heart of the Netherlands Life Sciences and Health industry Why locate your life sciences company in the Utrecht Region? Utrecht is at the heart of the Netherlands life sciences industry
More informationEuropean companies outpace American counterparts in R&D investment growth for the first time in five years
IP/08/1504 Brussels, 15 October 2008 European companies outpace American counterparts in R&D investment growth for the first time in five years R&D investment by EU companies has increased by 8.8% compared
More informationUtrecht Region. A key role in the Netherlands medical technology industry. Why locate your medical technology company in the Utrecht Region?
Utrecht Region A key role in the Netherlands medical technology industry Why locate your medical technology company in the Utrecht Region? The medical technology focus within the region s life sciences
More informationEarly Valuation. Company Portfolio
Early Valuation Company Portfolio The current strategy Idea PoC Regulatory Clinical Development Basic Science / Experts Operations Marketing / KOL Commercial Health Innovation Technology Transfer 1 I d
More informationGlobal Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner
Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis
More informationOther appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT.
Executive Committee Guido Oelkers Chief Executive Officer Born 1965. Employed since 2017. PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London,
More informationOwnership/ Partnership/ Principal. None None None Lantheus Medical Imaging (DSMB) NIH (DSMB)* None None None None None None
AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (Comprehensive) ACCF/AHA 2013 GUIDELINE FOR THE MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION (October, 2012) Committee Member Patrick T. O Gara,
More informationStarpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationKaro Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
More informationResearch Patents in Biotech SMEs
Research Patents in Biotech SMEs Doorways, Obstacles, Fortifications & Bridges Neil Thomas PhD Director of Intellectual Property, Genetrix Group, Madrid, Spain. Agenda 1. Introduction to Genetrix Definition
More informationMedtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year
www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for
More informationLIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTriton Technology Fund
Triton Technology Fund Presentation to Dean s Engineering Council March 22, 2013 Generate Returns for LPs/GPs Motivation for Fund Catalyze translation of UCSD discoveries for the benefit of society Enable
More informationCollegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business
More informationAMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014
Sector insights The healthcare market is highly complex with global products delivered through local services and channels. The healthcare value chain is intricate, diverse and interdependent. It is a
More informationReport of the DTL Partner Advisory Committee meeting November 23 rd 2017, h
Report of the DTL Partner Advisory Committee meeting November 23 rd 2017, 14.00-17.00 h Meeting location: DTL, Jaarbeurs Innovation Mile, Jaarbeursplein 6, 3521 AL Utrecht Attendees: Formal representatives
More informationCrack the Code: Demystify the Success Factors for Career Development
Crack the Code: Demystify the Success Factors for Career Development March 1, 2014, Saturday Rutgers University 675 Hoes Lane West Piscataway, NJ 08854 Sino-American Pharmaceutical Professionals Association
More informationPlease complete the applicable rows in the following table. Monetary amounts are on an annual basis.
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2016 Name: Shelby D. Reed, PhD Title: Professor Address: PO Box 17969, Durham, NC 27715 Please complete the applicable rows in the following table.
More informationEuropean Trends in Healthcare Investments and Exits 2018
European Trends in Healthcare Investments and Exits 2018 ANNUAL REPORT 2018 Nooman Haque Managing Director Life Science & Healthcare Bobby Anderson Senior Associate Life Science & Healthcare Vojtech Trebicky
More informationFunding New Innovations
Funding New Innovations Dr Belinda Clarke Lead Technologist, Biosciences (Synthetic Biology) email: belinda.clarke@tsb.gov.uk twitter: @Belinda_Clarke What is the problem we are addressing? Business investment
More informationLycera Corporation. Summary. Operating Partner (October 2016 Present)
PAUL JAI SEKHRI Summary 30 years of deep operational experience in life sciences including general management, corporate and business strategy, technology identification and drug development, business
More informationFDA Centers of Excellence in Regulatory and Information Sciences
FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in
More informationFor personal use only
2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor
More informationPresentation to Medicon Valley Alliance Crescendo Conference. Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners
CHINA GLOBAL CHINA Presentation to Medicon Valley Alliance Crescendo Conference Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners October 2013 0 We are an Ally and a Bridge. We are
More informationCourse Goals/Objectives. The course has five objectives:
NYU Langone Medical Center Postdoctoral Program and the Sackler Institute for Graduate Biomedical Sciences Fundamentals of Technology Commercialization Course Leader: Dr. Sadhana Chitale Class meets Wednesdays,
More informationDCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the
More informationThe partner of choice for self-care products
The partner of choice for self-care products Venture Life Group plc Full Year Results Presentation 2017 22 March 2018 2017 highlights Revenues up 12% to 16.1m (2016: 14.3m) Gross profit increased 18% to
More informationCDMO Partnering Strategies for Managing a Broad Portfolio of Molecules: A Novel Biopharma s Approach. AAPS Workshop November 12 th 2017
CDMO Partnering Strategies for Managing a Broad Portfolio of Molecules: A Novel Biopharma s Approach AAPS Workshop November 12 th 2017 Transforming the right molecules into the best medicines TM We are
More informationGOALS FOR PRESENTATION
Shubha Ghosh Professor of Law Associate Director, INSITE University of Wisconsin, Madison GOALS FOR PRESENTATION Background Major Issues Policy Concerns 2 My Background PhD in Economics from Michigan and
More informationPlease complete the applicable rows in the following table. Monetary amounts are on an annual basis.
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2015 Name: Patrick Pun, MD Title: Asasistant Professor of Medicine Address: DCRI Please complete the applicable rows in the following table. Monetary
More informationAre Biotechnology Startups Different?
Are Biotechnology Startups Different? Hervé Lebret Ecole Polytechnique Fédérale de Lausanne Vice-Presidency for Innovation, CH-1015 Lausanne, Switzerland Email: herve.lebret@epfl.ch Phone: +41 21 693 70
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationInternational Strategy Development Training: a personal strategic development workshop for Life Sciences Executives of SMEs
International Strategy Development Training: a personal strategic development workshop for Life Sciences Executives of SMEs Do you want to strengthen your business plan for your company?, or refresh your
More information9 Vaccine SMEs' Needs
9 Vaccine SMEs' Needs As in most innovative sectors, SMEs play a critical role in bridging basic discoveries from academic research to clinical development 36. This could be seen over the last decade with
More informationLife Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. Long Island JLL Research
Life Sciences Long Island 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research Suffolk County Stony Brook University serves as an integral part of the research corridor
More informationLaunch of new transatlantic specialty pharma company
For immediate release Thursday 1 March 2007 EUSA Pharma Inc ( EUSA Pharma or the Company ) Launch of new transatlantic specialty pharma company EUSA Pharma raises $175m for both the acquisition of OPi
More informationTrends in Healthcare Investments and Exits 2018
Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview
More informationDigital Health Startups A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationDNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile DNA2.0 Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market research
More informationIndustry Advisory Board Harper Cancer Research Institute
Industry Advisory Board Harper Cancer Research Institute Gaylene Anderson, M.B.A. US Director Contracts and Alliance Management Boehringer Ingelheim Pharmaceuticals Gaylene is the US Director of Contracts
More informationFinancing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics
1 Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics Eric Dobmeier Chief Business Officer Life science startups are the only companies that are forced to define their
More informationVentureSource Europe -- 3Q 2014
Europe -- 3Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, and liquidity. The included charts and graphs offer a
More informationexecutives are often viewed to better understand the merits of scientific over commercial solutions.
Key Findings The number of new technology transfer licensing agreements earned for every $1 billion of research expenditure has fallen from 115 to 109 between 2004 and. However, the rate of return for
More informationHealth & Social Care Industrial Innovation
Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging
More informationDigital Health, Technology and Life Sciences. Skip Fleshman
Digital Health, Technology and Life Sciences Skip Fleshman General Partner skip@assetman.com @SkipFleshman, @AMV Firm Facts AMV invests in early stage startups spanning digital health, technology and life
More informationMichael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co.
Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co. Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co. Risk taking: the key to securities law
More informationIgor Fisch. New candidate, independent
Igor Fisch New candidate, independent Igor Fisch is a co-founder of Selexis SA, a biotech company based in Switzerland. He grew the company from inception to profits in less than 5 years with up to > 5MCHF
More informationBecton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationManagement Team. Bruce C. Cozadd Chairman and Chief Executive Officer
Bruce C. Cozadd Chairman and Chief Executive Officer Bruce Cozadd joined Jazz Pharmaceuticals at its inception and was appointed Jazz Pharmaceuticals Chief Executive Officer in April 2009. From 2003 until
More informationScience - Industry Relationships in High-tech Sectors: Transatlantic Perspectives
Science - Industry Relationships in High-tech Sectors: Transatlantic Perspectives OECD / BMB+F Conference on Industry - Science Relationships Berlin, October 16-17th, 2000 no. 1 1. Empirical Basis Higher
More informationThe Next Generation: Top 20 Life Science Startups to Watch in 2017
The Next Generation: Top 20 Life Science Startups to Watch in 2017 1/3/2017 3:19:44 PM January 9, 2017 By Mark Terry, BioSpace.com Breaking News Staff BioSpace (DHX) is proud to present its NextGen Class
More informationReference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew.
Reference List Cha, Myoung., and Theresa Lorriman. February 2014. Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew. September 24, 2015. Pharmaceuticals: Value over Volume. Financial
More informationUsing Academic Licensing Agreements to Promote Global Social Responsibility
Using Academic Licensing Agreements to Promote Global Social Responsibility Equitable Licensing of Medical Research Results Charité - Universitätsmedizin Berlin April 26, 2009 Dr. Ashley J. Stevens Executive
More informationGREATER MONTRÉAL Life Sciences & Health Tech hub
GREATER MONTRÉAL Life Sciences & Health Tech hub Christelle Fasano, PharmD Director, Business Development Life Sciences & Health Technologies Foreign Investments 2018 1 01 Life sciences: a strategic sector
More informationMichael P. Ridley, Director. NYSTAR High Performance Computing Program
NYSTAR High Performance Computing Program Michael P. Ridley, Director NYSTAR High Performance Computing Program David A. Paterson, Governor Edward Reinfurt, Executive Director Outline 1 Program Goals 2
More informationNew York City Healthcare Venture Capital Report 2018
New York City Healthcare Venture Capital Report 2018 Introduction We are delighted to bring you the first annual New York City Healthcare Venture Capital Report 2018. The goal is to provide entrepreneurs,
More informationBOARD OF DIRECTORS. PETER WEHRLY Chair
BOARD OF DIRECTORS PETER WEHRLY Chair Peter Wehrly is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). Peter held
More informationPurvi B. Maniar Member of the Firm
Purvi B. Maniar Member of the Firm New York 250 Park Avenue New York, New York 10177 Tel: 212-351-3757 Fax: 212-878-8600 St. Louis Tel: 314-395-2775 pmaniar@ebglaw.com PURVI B. MANIAR is a Member of the
More informationVenture Capital Search Highlights
Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more
More informationFlorida Venture Capital Highlights
InternetCoast Florida Innovation Highlights Series Florida Venture Capital Highlights 2013 2017 2017 Florida Investment Activity Best Since 2000 InternetCoast January 2018 Dale Gregory President, InternetCoast
More informationKate Pretty Lecture Thursday 8 March Pascal Soriot, CEO AstraZeneca. What Science Can Do The Cambridge Cluster at a Pivot Point
Kate Pretty Lecture Thursday 8 March 2018 Pascal Soriot, CEO AstraZeneca What Science Can Do The Cambridge Cluster at a Pivot Point Introduction Thank you for your invitation and warm welcome to Homerton
More information(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K
DCRI Commercial relationships Tracking Form Year: 2018 Name: Adrian Hernandez, M.D. Title: Vice Dean, Clinical, School of Medicine Address: 200 Trent Dr., Durham NC 27710 Please complete the applicable
More information56 The Milken Institute Review
56 The Milken Institute Review tk Financing High-Risk Medical Research A Proposal from FasterCures By Melissa Stevens tk First Quarter 2016 57 In the past few years, the media has showered us with headlines
More informationFUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS
INDUSTRY RE FUNDS 1969 to present Industry surveys, quarterly and annual fund reports 9,240+ venture capital and private equity funds Venture capital and buyout funds that have invested in companies Name
More information